-
Signature
-
/s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
-
Stock symbol
-
XLO
-
Transactions as of
-
Oct 26, 2021
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
10/26/2021, 08:31 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
XLO |
Common Stock |
Conversion of derivative security |
|
+1.48M |
|
|
1.48M |
Oct 26, 2021 |
See explanation |
F1, F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
XLO |
Series B Preferred Stock |
Conversion of derivative security |
$0 |
-1.25M |
-100% |
$0.00* |
0 |
Oct 26, 2021 |
Common Stock |
1.25M |
|
See explanation |
F1, F2, F3 |
transaction |
XLO |
Series C Preferred Stock |
Conversion of derivative security |
$0 |
-227K |
-100% |
$0.00* |
0 |
Oct 26, 2021 |
Common Stock |
227K |
|
See explanation |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Takeda Pharmaceutical Co Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses: